Consultation to reduce medication side effects using genetic information
Evaluating the Effectiveness of a Personalized Therapeutics Clinic (PTC) Intervention on Drug-Drug Interactions (DDIs) and Drug-Gene Interactions (DGIs)
This study is testing if a personalized clinic can help adults taking multiple medications by using their genetic information to reduce side effects and improve how their medicines work.
Quick facts
| Phase | Not applicable |
|---|---|
| Study type | Interventional |
| Enrollment | 1300 (estimated) |
| Ages | 18 Years and up |
| Sex | All |
| Sponsor | University of Chicago Academic / other |
| Locations | 1 site (Chicago, Illinois) |
| Trial ID | NCT05166694 on ClinicalTrials.gov |
What this trial studies
This study evaluates the effectiveness of a Personalized Therapeutics Clinic (PTC) in helping patients manage drug-drug and drug-gene interactions. Participants will undergo genetic testing to identify variations that may affect their response to medications, aiming to improve prescribing decisions and reduce side effects. The study will involve adult patients prescribed multiple medications and will last approximately nine months. The PTC will provide tailored advice based on genetic insights to enhance medication safety and efficacy.
Who should consider this trial
Good fit: Ideal candidates are adults aged 18 and older who are prescribed five or more medications and are taking drugs with actionable pharmacogenomic information.
Not a fit: Patients who have undergone liver or kidney transplantation or those who have previously received genotyping from another source may not benefit from this study.
Why it matters
Potential benefit: If successful, this approach could significantly reduce medication-related side effects and improve treatment outcomes for patients with complex medication regimens.
How similar studies have performed: Other studies have shown promise in using pharmacogenomic information to guide medication management, indicating that this approach may be beneficial.
Eligibility criteria
Show full inclusion / exclusion criteria
Inclusion Criteria: 1. Adult participants cared for by a participating provider at University of Chicago Medical Center. 2. Participants must be at least 18 years of age. 3. Participants prescribed 5 or medication medications and taking a perpetrator drug or a drug with actionable pharmacogenomic information. Exclusion Criteria for Participants 1. Participants who have undergone, or are being actively considered for, liver or kidney transplantation. 2. Participation in another pharmacogenomic study. 3. Participants who have previously received genotyping from another source. 4. Inability to understand and give informed consent to participate. Inclusion of Women, Minorities, and Other Underrepresented Populations Individuals of all races and ethnic groups and genders are eligible for this trial.
Where this trial is running
Chicago, Illinois
- University of Chicago Medicine — Chicago, Illinois, United States (Recruiting)
Study contacts
- Principal investigator: Mark Ratain, MD — University of Chicago
- Study coordinator: Andre Hall
- Email: andrehall@bsd.uchicago.edu
- Phone: (773)834-0936
How to participate
- Review the eligibility criteria above with your treating physician.
- Visit the official trial page on ClinicalTrials.gov for the most current contact information and recruitment status.
- Contact the listed study coordinator or principal investigator to request pre-screening. Pre-screening is free and never obligates you to enroll.